

Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/N0457FD80AB2EN.html>

Date: March 2022

Pages: 807

Price: US\$ 2,500.00 (Single User License)

ID: N0457FD80AB2EN

Abstracts

Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research

and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 67, 81, 13, 209, 98 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 8 and 2 molecules, respectively.

Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration

details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Non-Alcoholic Steatohepatitis (NASH) - Overview
- Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics Development
- Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles
- Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects
- Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products
- Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Companies, 2022 (Contd..4)

Number of Products under Development by Companies, 2022 (Contd..5)

Number of Products under Development by Companies, 2022 (Contd..6)

Number of Products under Development by Companies, 2022 (Contd..7)

Number of Products under Development by Companies, 2022 (Contd..8)

Number of Products under Development by Companies, 2022 (Contd..9)

Number of Products under Development by Companies, 2022 (Contd..10)

Number of Products under Development by Companies, 2022 (Contd..11)

Number of Products under Development by Companies, 2022 (Contd..12)

Number of Products under Development by Companies, 2022 (Contd..13)

Number of Products under Development by Companies, 2022 (Contd..14)

Number of Products under Development by Companies, 2022 (Contd..15)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Target, 2022 (Contd..2)

Number of Products by Stage and Target, 2022 (Contd..3)

Number of Products by Stage and Target, 2022 (Contd..4)

Number of Products by Stage and Target, 2022 (Contd..5)

Number of Products by Stage and Target, 2022 (Contd..6)

Number of Products by Stage and Target, 2022 (Contd..7)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..4)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..5)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..6)
Number of Products by Stage and Mechanism of Action, 2022 (Contd..7)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, 2022
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, 2022 (Contd..1)
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, 2022 (Contd..2)
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, 2022 (Contd..3)
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, 2022 (Contd..4)
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, 2022 (Contd..5)
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, 2022 (Contd..6)
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, 2022 (Contd..7)
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, 2022 (Contd..8)
Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products, 2022
Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/N0457FD80AB2EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N0457FD80AB2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

